CAMP4 Secures Clearance for SYNGAP1 Patient Trial

The Tip Desk · October 18, 2026 · 3 min read

The company said a $50.1 million private-placement closing extended its expected funding horizon through the end of 2028.

CAMP4 Therapeutics Corporation (CAMP), a clinical-stage biopharmaceutical company developing regulatory RNA-targeting treatments, secured clearance in Australia and Argentina supporting initiation of the planned Phase 1/2 trial of CMP-002 in patients with SYNGAP1-related disorder. The regulatory advance moved the program closer to its first human study after successive updates centered on toxicology work and an initial clinical trial application.

The progression marked a change in the development work reported across the company's three updates. In March, CAMP4 said toxicology studies were ongoing to support future trial applications. By May, it had submitted its first application in Australia. The latest clearances covered Australia's Therapeutic Goods Administration and local Human Research Ethics Committee, along with Argentina's medicines regulator, establishing regulatory permission to initiate the Phase 1/2 study in those jurisdictions.

Chief Executive Josh Mandel-Brehm said CAMP4 was focused on initiating the trial and continuing activation work in additional jurisdictions. He said there were no approved disease-modifying treatments for SYNGAP1. The clearances concerned permission to begin clinical testing; the company described the planned study as its first-in-human trial of CMP-002.

The advance followed CAMP4's decision, reported in its full-year update, to bring the SYNGAP1 program to the forefront of its pipeline. After analyzing the single- and multiple-ascending-dose portions of a Phase 1 trial of CMP-001, the company had paused further investment in that separate candidate and said it would explore partnership opportunities. CMP-002 consequently occupied the center of the latest clinical update.

CAMP4 described its approach as targeting regulatory RNAs to amplify messenger RNA and increase protein expression. The company said its platform was designed to generate candidates for genetic diseases in which modest increases in healthy protein could have therapeutic benefits. That development strategy also extended beyond its internal pipeline: during 2025, CAMP4 entered a collaboration with GSK covering targets relevant to neurodegenerative and kidney diseases and received a $17.5 million upfront payment.

Cash and cash equivalents were $86.4 million at June 30, down from $99.2 million at March 31. The additional private-placement proceeds arrived after the second quarter ended, so they were outside the reported quarter-end cash balance. The closing completed the second tranche of the financing initially announced in September 2025, when CAMP4 had received approximately $50 million in gross proceeds.

The financing lengthened the company's stated funding horizon. CAMP4 now expects its cash resources to support planned activities through the end of 2028, compared with its previous expectation of funding into 2028. The company presented that outlook alongside preparations for the CMP-002 trial, without providing a separate spending forecast for the study.

The reported quarterly loss widened substantially, although the company attributed most of the increase to a financing-related accounting item. Net loss was $33.5 million, against $12.6 million a year earlier. CAMP4 said the increase was primarily driven by a $20.9 million non-cash loss from remeasuring the derivative tranche liability associated with the September 2025 private placement.

The change was smaller at the operating level: operating loss was $13.38 million, compared with $13.03 million a year earlier. Research and collaboration revenue totaled $1.779 million, while total operating expenses were $15.159 million. Research and development spending was $10.8 million, primarily associated with clinical and preclinical study costs.

General and administrative expenses were $4.3 million. CAMP4 attributed their increase to higher stock-based compensation, partly offset by reduced facilities costs.

The next clinical step remained trial initiation. CAMP4 had also submitted applications in the European Union and United Kingdom to support broader enrollment across multiple sites. The company expects the Phase 1/2 trial to begin in the fourth quarter of 2026, specifying a narrower launch window than the second-half timing given in May.